 Hi, I'm Chris Thompson from Investor Intel, and today I'm speaking with David Riegan, the CEO of Sonat Nanotech. S-O-N-A is the ticker symbol on the Canadian Security Exchange. How are you today, David? I'm great, Chris. Thanks for having me on. Your company is a nanotechnology life sciences company. Maybe for investors who may not know much about what that is, can you give us a brief background on it? Sure. So Sonat Nanotech is a company that's been built up around its proprietary and patent-pending gold nanoraw technology. And really what that is is the technology that enables us to manipulate particles of gold on the nanoscale uniquely without the use of toxins. And that, I'll tell you a little bit further on, but why that's important. But we've built the company up and we've got two focuses leveraging on that technology. Okay. And so what are the focuses that the technology is used for? So the gold nanoraws can be used in a variety of different applications. We've built up an expertise in lateral flow rapid tests. So the ones like pregnancy tests and of course the COVID tests that we've all seen owe so many times in the past year and a half, sadly. The second area is a longer-term focus for us in terms of researching out the capabilities of our particular technology that will enable them to be used in the body for such things as photothermal applications and targeted drug delivery. Okay. So are you, and how are you testing these applications? Are you working with various universities? I saw there was a recent announcement with U of T. Maybe you can go into that a bit. Yeah. We're very fortunate to be working with Dr. Warren Chan at the leading Bioengineering Institute in Canada and their lab. And we're very excited. And what we'll be exploring in the studies that will be announced in the future, we expect, is the biocompatibility of our gold nanorawds. Again, going back to this idea that we uniquely can make gold nanorawds without the use of toxins. And that, of course, you can imagine, Chris, is going to be extremely important when we start taking these tiny gold nanorawds and putting them in the body for various medical applications. Now, I've got to say this is an emerging area of science and medicine. And it is many years from fully being developed. And it will rely upon researchers and entrepreneurs from around the world. But we believe we can play a very important role in that. And what are the sort of the major diagnostic tests that you would be using the gold nanorawds with? So there are a variety of different rapid tests we're working on right now. A concussion test, importantly, rapid concussion test doesn't exist that can be used within a number of minutes field side. We're working on, of course, a COVID test. And we have a COVID test that uses saliva that we're very excited about. We partnered with a great company in the U.S. that's already FDA certified called Arlington Scientific. And to date, there's no rapid saliva test that's been approved. We think that's one that can make, can play a very, very important role in limiting the pandemic. We'll just follow this train of thought for a second with the COVID test. And that relationship, will that sort of bring revenue into the company sort of in the next year or so? Well, it's interesting as we talk about the two different areas of focus the company has right now. The first one on diagnostics, that we expect much near term revenues to accrue from there, particularly our COVID saliva test, which is in the midst of an IRB approval in the U.S. And we expect to kick off a clinical study for it in the coming weeks. And now, what is your background with the company? So I've been with the company for about a year and a half. It's been a very exciting time for the company. The company was in a startup phase of the time and the company has grown a fair amount and has learned a great deal in the last year and a half. It's been exciting times and we're very pleased at this stage with the developments both on the longer term research prospects for our gold nanorod technology, as well as the near term revenues associated with, for what we expect to be revenues associated with an antigen test for saliva in the U.S. in the coming months. So as investors looking at your company to make an investment in the biotech space, what can they expect from the new flow, say for the next six months or so into 2022? Well, Chris, we've got a number of things going on on both fronts. First, on the fundamental research side, which is we believe the bigger opportunity, frankly, but much, much more longer term because of those medical applications and the work that needs to be done by many around the world. But nonetheless, with an MOU with the University of Toronto's Bioengineering Institute announced, we hope to have more to discuss around that as far as some of the specific studies that we think can be quite exciting because we expect to be able to prove out the biocompatibility of our gold nanorods. On the other side of the company, on the rapid diagnostics front, we've already announced that we are anticipating a clinical trial for our saliva test in the U.S. with a U.S. partner who is FDA certified and has a great deal of experience working with the FDA and has extremely strong distribution in the U.S. So we think there'll be a number of different developments to be speaking about in the coming months. If all goes well. Well, great. We look forward to following your company and interviewing you again soon when you have some additional news. And I appreciate your time. Today, I was speaking with David Regan, who is the CEO of Sonon Nanotech, ticker symbol as S-O-N-A on the CSE. Thanks for your time, David. Thanks, Chris. Look forward to catching up next time.